Form 3: Simcere Zaiming Discloses 338,636 NXTC Shares; Ownership Chain Detailed
Rhea-AI Filing Summary
Simcere Zaiming, Inc. filed a Form 3 reporting initial ownership of 338,636 shares of NextCure, Inc. (NXTC) as of 06/20/2025. The filing states these shares are directly held by Simcere Zaiming and describes the chain of ownership through Jiangsu Zaiming, Hainan Zaiming and Simcere Pharmaceutical Group, naming key executives who may share voting and investment power. The reporting person disclaims beneficial ownership except for pecuniary interest.
Positive
- None.
Negative
- None.
Insights
TL;DR: Initial disclosure of a 338,636-share stake by an affiliate through a corporate ownership chain; informational, not transactional.
The Form 3 documents an initial reporting of 338,636 common shares in NXTC held directly by Simcere Zaiming, Inc. It clarifies the ownership chain and identifies individuals with shared voting and investment power but contains no purchase price, transaction date beyond the event date, or derivative positions. The filing is a routine disclosure required under Section 16 and is neutral in market impact absent more context on stake size relative to float.
TL;DR: Clear chain of ownership and power is disclosed; the reporting person disclaims beneficial ownership beyond pecuniary interest.
The filing provides appropriate disclosure of indirect control through multiple subsidiaries and names executives associated with shared powers, which supports transparency around potential control and related voting influence. The explicit disclaimer of beneficial ownership (except pecuniary interest) is standard. No governance changes or transactions are reported here.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming" or the "Reporting Person") and may be deemed to be indirectly beneficially owned by the other persons. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that the Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
